The company has been under performing for years now. The TCR trial at the NCI is delayed yet again, the 3rd Gen CAR has an FDA hold still placed on it and Ad-RTS-hIL-12 is useless in rGBM like it was in melanoma and breast cancer. Meanwhile, the competition continues to move forward.
News 
Market Data 
Discover 
